Navigation Links
Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
Date:2/12/2008

Adjusted net income excluding selected items(1)

Q4 2007: euro 1,429 million (up 4.5%), i.e. euro 1.07 per share (up 5.9%, or up

18.3% in U.S. dollars(2))

FY 2007: euro 6,961 million (up 5.9%), i.e. euro 5.17 per share (up 5.9%, or up

15.7% in U.S. dollars(2))

BRIDGEWATER, N.J., Feb. 12 /PRNewswire-FirstCall/ -- In order to give a representation of our underlying economic performance, we present and explain an adjusted(1) income statement. We also report adjusted net income and adjusted EPS (excluding selected items) in U.S. dollars(2) in order to facilitate comparisons with the majority of major pharmaceutical groups. The 2007 consolidated income statement is provided in the Appendices. Full-year consolidated net income for 2007 was euro 5,263 million, against euro 4,006 million for 2006.

Fourth quarter

-- Net sales down 2.2% on a comparable basis (or 6.0% on a reported basis)

at euro 6,911 million

-- Growth of 5.7% in pharmaceuticals net sales after excluding the impact

of generics of Ambien(R) IR in the United States and Eloxatin(R) in

Europe(3)

-- Growth in earnings despite the negative effects of the euro/dollar

exchange rate and of earlier shipments of influenza vaccines than in

2006

2007 full year: euro 5.28 adjusted EPS with selected items; euro 5.17 excluding selected items
-- Net sales up 2.8% on a comparable basis (down 1.1% on a reported basis)

at euro 28,052 million

-- Growth of 6.4% in Pharmaceuticals net sales after excluding the impact

of generics of Ambien(R) IR in the United States and Eloxatin(R) in

Europe(3); 14.5% growth in Vaccines net sales

-- Lantus(R): First insulin brand to exceed euro 2 billion of sales

-- Marked decline in selling and general expensed items

Worldwide presence(1) of Aprovel(R)/ Avapro(R)/ Karvea(R)

Change Change

on a on a

comparable comparable

euro million Q4 2007 basis FY 2007 basis

Europe 233 +1.7% 922 +5.1%

United States 129 +4.0% 507 +7.2%

Other Countries 118 +26.9% 422 +19.9%

TOTAL 480 +7.6% 1,851 +8.8%

Fourth-quarter worldwide sales of Aprovel(R)/Avapro(R)/Karvea(R) were euro 480 million, an increase of 7.6%.

In November, the United States Food and Drug Administration (FDA), based on efficacy data from two clinical trials involving over 1,200 patients with moderate or severe high blood pressure, approved Avalide(R) (irbesartan, hydrochlorothiazide) as the first combination therapy for initial use in patients likely to need multiple drugs to achieve blood pressure goals.

Net sales by division - Human Vaccines

Fourth-quarter consolidated net sales for the Human Vaccines business were down 15.3% at euro 649 million. This decrease reflects earlier shipments of influenza vaccines than in 2006, when a substantial proportion of shipments were delayed to the fourth quarter. As a result, net sales of influenza vaccines were down 40.4% at euro 245 million. Excluding influenza vaccines, net sales for the Human Vaccines business rose by 13.8% in the quarter.

Adacel(TM) (adult and adolescent tetanus-diphtheria-pertussis booster) and Menactra(R) performed very strongly in the fourth quarter, with net sales up 44.0% to euro 38 million and up 73.5% to euro 71 million respectively due to improved supply. An extension to the license for Menactra(R), covering children aged 2 to 10, was obtained in the United States in October 2007.

Over the full year, consolidated net sales for the Human Vaccines business rose by 14.5% to euro 2,778 million. Net sales of Menactra(R) advanced by 86.1% to euro 415 million, and net sales of Adacel(TM) increased by 64.5% to euro 234 million. Sanofi pasteur produced over 180 million doses of seasonal influenza vaccines in 2007, reinforcing its position as world leader: the number of doses shipped represented an estimated 40% of the world market(5). Excluding sales of H5N1 vaccines, sales of seasonal influenza vaccines rose by 2.6%.

Change Change

on a on a

Q4 2007 comparable FY 2007 comparable

euro million net sales basis net sales basis

Influenza Vaccines* 245 -40.4% 766 -3.0%

Polio/Pertussis/Hib Vaccines 142 0.0% 660 +5.1%

Meningitis/Pneumonia Vaccines 85 +57.4% 482 +65.1%

Adult Booster Vaccines 70 -2.8% 402 +26.8%

Travel & Other Endemics Vaccines 76 +20.6% 327 +14.7%

Other Vaccines 31 +29.2% 141 +23.7%

TOTAL 649 -15.3% 2,778 +14.5%

* seasonal and pandemic influenza vaccines

Fourth-quarter sales at Sanofi Pasteur MSD, the joint venture with Merck & Co in Europe, rose by 44.4% on a reported basis to euro 371 million, buoyed by the success of Gardasil(R) (net sales of euro 160 million).

Sanofi Pasteur MSD began marketing Gardasil(R) in Europe at the end of 2006. This product, the first vaccine against papillomavirus infections (which cause cervical cancer), is now sold in all 19 European countries covered by the joint venture.

Sanofi Pasteur MSD achieved 2007 full-year sales of euro 1,040 million, up 43.6% on a reported basis. Net sales of Gardasil(R) for the year totaled euro 341 million. Sanofi Pasteur MSD sales are not consolidated by sanofi-aventis.

(5) Internal estimate

Net sales by geographic region

Change on a Change on a

Q4 2007 comparable FY 2007 comparable

euro million net sales basis net sales basis

Europe 3,056 -0.4% 12,184 -0.4%

United States 2,181 -8.5% 9,474 +3.8%

Other Countries 1,674 +3.8% 6,394 +7.8%

TOTAL 6,911 -2.2% 28,052 +2.8%

Net sales fell slightly in Europe in the fourth quarter, mainly as a result of the continuing decline in net sales in Germany. Over 2007 as a whole, net sales were down by 0.4%, with the introduction of generics of Eloxatin(R) paring approximately 1.6% off growth for the period.

In the United States, fourth-quarter net sales were down 8.5%, affected by generics of Ambien(R) IR (which went off patent on April 20) and lower influenza vaccine sales (a substantial proportion of shipments having been postponed to the fourth quarter in 2006, making for a tough comparative). Excluding the effect of generics of Ambien(R) IR and of timing differences in shipments of vaccines, net sales growth in the United States would have been 14.4%. Over 2007 as a whole, net sales rose by 3.8%. After excluding the effect of generics of Ambien(R) IR from April 2007, net sales in the United States rose by 15.1%.

Fourth-quarter net sales in "Other Countries" increased by 3.8%, below the full-year growth rate. Excluding the effect of the repurchase of inventories from Astellas and Chugai following the signature of agreements with these two companies on the buyout of several products and the effect of timing differences in shipments of vaccines, fourth-quarter sales growth in this region would have been 7.0%.

Adjusted consolidated income statement

The adjusted consolidated income statement is presented in Appendix 3.

Refer to Appendix 1 for a definition of "adjusted net income", and to appendix 4 for a reconciliation of the consolidated income statement to the adjusted consolidated income statement.

Fourth quarter of 2007

The fourth quarter saw a marked fall in the dollar against the euro of 12.4%, compared with an average fall of 8% over the first nine months of the year.

Sanofi-aventis net sales for the fourth quarter of 2007 fell by 6.0% on a reported basis to euro 6,911 million.

Gross profit was euro 5,257 million. The gross margin ratio was 76.1%, against 76.5% for the fourth quarter of 2006. Royalty income rose by 36.0%, mainly due to a sharp rise in sales of Plavix(R) in the United States versus the fourth quarter of 2006 (when the product faced competition from a generic version), and despite the discontinuation of royalties on fipronil. The ratio of cost of sales to net sales was 28.4% (compared with 26.6% in the fourth quarter 2006), largely as a result of the introduction of generics of Ambien(R) IR in the United States and timing differences in sales of influenza vaccines between 2006 and 2007.

Research and development expenses rose by 5.0%. This includes the effect of discontinuing development of the ciclesonide/formoterol combination, the rights for which were returned to Nycomed.

Selling and general expenses totaled euro 1,996 million, representing a marked reduction of 7.3% relative to the fourth quarter of 2006. The ratio of selling and general expenses to net sales was 28.9%, against 29.3% in 2006.

Operating income - current(1) fell by 13.7%, and represented 28.4% of net sales versus 30.9% in 2006. This fall was due entirely to the euro/dollar exchange rate and to timing differences in sales of influenza vaccines.

A restructuring charge of euro 87 million (euro 60 million after tax) was recognized to cover a new program of cost adaptation measures in Germany.

Net financial expenses came to euro 28 million, against net financial income of euro 66 million in the comparable period of 2006 (the fourth quarter of 2006 included a gain of euro 101 million on the sale of the interest in Rhodia). Interest expense on debt was euro 47 million, compared with euro 36 million for the fourth quarter of 2006, with the positive effect of debt reduction more than canceled out by the impact of higher interest rates.

Income tax expense was euro 464 million, compared with euro 534 million in the fourth quarter of 2006. The reported tax rate was 25.1%, against 27.2% for the comparable period of 2006. The settlement of various tax disputes resulted in the release of euro 93 million of provisions (treated as a selected item).

The share of profits from associates was euro 178 million, versus euro 50 million for the fourth quarter of 2006, thanks to the sharp rise in sales of Plavix(R) in the United States. The share of after-tax profits from territories managed by BMS (primarily the United States) under the Plavix(R) and Avapro(R) alliance was euro 149 million, versus euro 12 million in the fourth quarter of 2006.

Minority interests totaled euro 97 million, compared with euro 103 million in the fourth quarter of 2006. This line includes the share of pre-tax profits paid to BMS from territories managed by sanofi-aventis (euro 96 million, compared with euro 98 million in the fourth quarter of 2006).

Adjusted net income was up 6.2% at euro 1,462 million, and adjusted earnings per share (adjusted EPS) was euro 1.09 (6.9% up on the 2006 fourth- quarter figure of euro 1.02), based on an average number of shares outstanding of 1,335.3 million in the fourth quarter of 2007 and 1,348.8 million in the fourth quarter of 2006.

Excluding selected items (see Appendix 5), adjusted net income was euro 1,429 million, 4.5% up on the fourth quarter of 2006 (euro 1,368 million), and adjusted EPS was euro 1.07, 5.9% up on the fourth quarter of 2006 (euro 1.01).

Expressed in U.S. dollars(2) and excluding selected items, adjusted net income was $2,071 million (up 17.3% on the 2006 fourth-quarter figure) and adjusted EPS was $1.55 (up 18.3% on the 2006 fourth-quarter figure).

(2) U.S. dollar figures obtained by translating euro-denominated figures at the average exchange rate for the period: 1.449 for Q4 2007 (1.290 for Q4 2006) and 1.371 for FY 2007 (1.256 for FY 2006)

2007 full year

Sanofi-aventis generated 2007 full-year net sales of euro 28,052 million, down 1.1% on a reported basis.

Gross profit was down 1.4% at euro 21,636 million. The gross margin ratio was 77.1%, versus 77.3% in 2006. The availability of generics of Ambien(R) IR from April 2007 adversely affected the ratio of cost of sales to net sales, which rose from 26.6% to 27.0%. The weakening dollar and the discontinuation of royalties on fipronil restricted growth in other revenues to 3.5% (to euro 1,155 million), despite strong growth for Plavix(R) in the United States.

Research and development expenses rose by 2.4% (5.5% excluding the effect of exchange rates).

The cost adaptation measures initiated in 2006 and 2007, combined with tight cost control, helped to reduce the ratio of selling and general expenses to net sales by additional 1.4 points compared with 2006, to 26.9%. Overall, selling and general expenses fell by 5.8% year on year, to euro 7,554 million. Excluding the effect of exchange rates, selling and general expenses decreased by 2.1%.

Other current operating income (net of expenses) totaled euro 215 million, against euro 275 million in 2006. In 2007, this line includes an expense of euro 61 million (euro 42 million after tax, treated as a selected item) on the harmonization of welfare and healthcare plans for the Group's retirees.

Operating income - current(1) was virtually unchanged at euro 9,617 million. The operating margin ratio improved by 0.4 of a point to 34.3%. Excluding the effect of exchange rates, operating income - current advanced by 6.5%.

The financial statements include a restructuring charge of euro 137 million (euro 95 million after tax) for the ongoing cost adaptation program launched in France in 2006 and for a new program initiated in Germany.
In 2006, the financial statements included:

-- gains on disposal of euro 553 million, mainly on the sale of the

Exubera(R) rights (euro 460 million, or euro 384 million after tax) and

the sale of the residual stake in the Animal Nutrition business (euro

45 million, or euro 31 million after tax);

-- impairment losses of euro 217 million taken against property, plant and

equipment and intangible assets, including euro 114 million for the

impairment of industrial assets associated with Ketek(R).

Net financial expense was euro 139 million, compared with euro 80 million in 2006. Interest expense on debt amounted to euro 223 million, compared with euro 286 million in 2006.

Income tax expense totaled euro 2,572 million, versus euro 2,816 million in 2006. The 2007 figure includes a net gain of euro 337 million relating to movements in provisions for tax risks and settlements of tax disputes, and a deferred tax expense of euro 51 million related to cuts in tax rates in Germany, Spain and the United Kingdom. The 2006 figure was influenced by the low income tax charge arising on the Exubera(R) gain. The effective tax rate for 2007 was 30.6%, unchanged from the 2006 figure.

The share of profits of associates was euro 760 million, against euro 559 million for 2006. The share of after-tax profits from territories managed by BMS under the Plavix(R) and Avapro(R) alliance was euro 525 million, versus euro 320 million in 2006. There was an increase in the contribution from Merial.

Minority interests came to euro 419 million, compared with euro 393 million in 2006. This line includes the share of pre-tax profits paid to BMS from territories managed by sanofi-aventis (euro 403 million, versus euro 375 million in 2006).

Adjusted net income rose by 1.0% to euro 7,110 million, while adjusted earnings per share (adjusted EPS) was euro 5.28 (1.0% higher than the 2006 figure of euro 5.23), based on an average number of shares outstanding of 1,346.9 million in 2007 and 1,346.8 million in 2006.

Excluding selected items (see Appendix 5), adjusted net income was euro 6,961 million (up 5.9% on the 2006 figure of euro 6,571 million), and adjusted EPS was euro 5.17 (up 5.9% on the 2006 figure of euro 4.88).

Expressed in U.S. dollars(2) and excluding selected items, adjusted net income was $9,544 million (up 15.6% on the 2006 figure) and adjusted EPS was $7.09 (up 15.7% on the 2006 figure).

(2) U.S. dollar figures obtained by translating euro-denominated figures at the average exchange rate for the period: 1.449 for Q4 2007 (1.290 for Q4 2006) and 1.371 for FY 2007 (1.256 for FY 2006)

2007 consolidated statement of cash flow and balance sheet at December 31, 2007

Operating cash flow before changes in working capital was euro 7,917 million, compared with euro 7,610 million in 2006.

Working capital needs increased by euro 811 million, compared with euro 1,006 million in 2006.

Investing activities generated a net cash outflow of euro 1,716 million over the period.

Acquisitions of property, plant and equipment and intangibles amounted to euro 1,610 million, essentially comprising investment in industrial plant and equipment and contractual payments for intangible rights. These acquisitions of intangible rights (euro 231 million in 2007) mainly comprise the buyout of commercial rights over products (including Panaldine(R) in Japan) and payments made under collaboration and marketing agreements with partners including Regeneron, Oxford BioMedica (TroVax(R)), UCB (Xyzal(R)), Crucell N.V. and Acambis.

Acquisitions of investments (euro 435 million) mainly comprised euro 186 million on the buyout of preferred shares issued by Carderm Capital LP (a subsidiary of sanofi-aventis) and euro 218 million on the purchase of 12 million shares in Regeneron, taking the interest held by sanofi-aventis to approximately 19% of the capital.

After-tax proceeds from disposals (euro 329 million) included receipt of the contingent CSL purchase consideration of $250 million.

After a dividend payout of euro 2,373 million and the acquisition of 29.4 million treasury shares for euro 1,806 million, net cash generated during 2007 was euro 1,561 million, enabling sanofi-aventis to reduce net debt from euro 5.8 billion at December 31, 2006 to euro 4.2 billion at December 31, 2007. Gearing stood at 9.5% at December 31, 2007, compared with 12.6% at December 31, 2006.

2008 Guidance(5)

Barring major adverse events, sanofi-aventis expects 2008 full-year adjusted EPS excluding selected items(1) to grow around 7%, calculated at constant euro/dollar parity (1,371). Sensitivity to the euro/dollar exchange rate is estimated at 0.5% of growth for a 1-cent movement in the exchange rate.

Dividend

At its February 11, 2008 meeting, sanofi-aventis Board of Directors established the agenda and the draft resolutions to be submitted to the Shareholders' Ordinary Annual General Meeting of May 14, 2008. It notably decided to propose to the General Meeting to approve a dividend of euro 2.07 per share. This would represent an increase of 18.3% on the previous year (euro 1.75). The dividend payment date will be May 21, 2008.

(1) Refer to Appendix 1 for a definition of financial indicators, and to Appendix 6 for details of selected items.
(5) Adjusted EPS excluding selected items for 2007 was euro 5.17.

Research and Development

Our R&D teams have made progress on the key objectives announced at the R&D Day in September 2007.

During 2007, 21 compounds moved into the development phase of which 16 in pharma. In 2007, sanofi-aventis filed submissions for the first-ever intradermic influenza vaccine and for Aquilda(R) (Satavaptan), a treatment for hyponatremia. The ongoing efforts to broaden access to Menactra(R) led to the granting of FDA approval in 2007 for the 2-10 age bracket.

A major collaboration agreement was signed with Regeneron, covering the discovery and development of human monoclonal antibodies, with the objective of bringing at least two compounds into development every year. Under this agreement, an antibody against the Interleukin-6 receptor (IL-6R) has already started clinical trials in rheumatoid arthritis. It is due to be followed by an antibody against Delta-like ligand-4 (Dll4), scheduled to start clinical development in 2008 in oncology.

A number of other collaboration agreements have been signed in the field of vaccines, including those with Acambis (to develop vaccines against Japanese encephalitis and West Nile virus), with SSI (to develop a new tuberculosis vaccine) and with Crucell (in monoclonal rabies antibodies), plus an alliance with the Institut Pasteur in malaria.

Progress to date on our ongoing clinical development suggests that we remain on track for our forecast of around 30 potential filings by end 2010.

The main developments in our R&D portfolio are described below:

Metabolic disorders

Results from phase IIb trials on AVE5530, a cholesterol absorption inhibitor, showed a significant reduction in LDL at different doses, confirming the potential benefits of this product. Its non-systemic mode of action opens up the possibility of avoiding drus, with the ratio of

selling and general expenses down 1.4 points at 26.9%

-- Earnings ahead of full-year guidance(4):

-- Business development highlights: signature of alliance agreements with

Regeneron, Acambis, Crucell and Oxford Biomedica, and buyout of rights

to several of our products in Japan

Share repurchase program and dividend

-- 29.4 million shares repurchased in 2007 for a total of euro 1.8 billion

-- A dividend increase of 18.3% to euro 2.07 per share proposed to the

Shareholders' Annual General Meeting

2008 guidance

Barring major adverse events, sanofi-aventis expects 2008 adjusted EPS excluding selected items(5) to grow around 7%, calculated at constant 2007 euro/dollar parity (1,371). Sensitivity to the euro/dollar exchange rate is estimated at 0.5% of growth for a 1-cent movement in the exchange rate. (see page 11)

(1) See Appendix 1 for a definition of financial indicators, and Appendix

6 for a description of selected items

(2) U.S. dollar figures obtained by translating euro-denominated figures

at the average exchange rate for the period: 1.449 for Q4 2007 (1.290

for Q4 2006) and 1.371 for FY 2007 (1.256 for FY 2006)

(3) Excluding net sales of Ambien(R) IR in the United States (from April)

and net sales of Eloxatin(R) in Europe

(4) Adjusted EPS excluding selected items up 13% at a constant 2006

euro/dollar rate (1.25) against guidance of 10% growth

(5) Adjusted EPS excluding selected items for 2007 was euro 5.17.

2007 fourth-quarter and full-year net sales
Unless otherwise indicated, all sales growth figures in this press release are

stated on a comparable basis(1). Sanofi-aventis generated fourth-quarter net sales of euro 6,911 million, down 2.2%. Exchange rate movements had an unfavorable effect of 4.2 points, mainly due to tg interaction. AVE5530 has the potential to be used as monotherapy or in combination with statins. A phase III program comprising a number of trials, including an evaluation over a 12- month treatment period, will start in the second half of 2008. Filing for approval is scheduled for the second half of 2010, both as monotherapy and in fixed combination with a statin.

After consultation with the healthcare authorities, the phase III program for the GLP-1 agonist AVE0010 will begin in the first quarter of 2008. The program will include over 3,000 diabetic patients and will evaluate a once-a- day injection of AVE0010 in combination with the principal existing treatments (metformin, sulfonylurea insulin), as well as a comparison with exenatide and a monotherapy study. Filing for approval is expected in 2010. A prolonged release formulation is currently being evaluated in phase I.

Results from phase IIb trials of AVE2268, a new renal SGLT2 inhibitor, are due in the first half of 2008, with phase III scheduled to start in the second half of 2008. This product has a novel action, and is expected to improve glycemic control at all stages of diabetes.

The program to develop rimonabant in diabetes already includes 3,400 out of the planned total of 5,700 patients. Results of the ARPEGGIO study, evaluating rimonabant in combination with insulin, will be presented to the American Diabetes Association in June 2008. Filing for approval in type II diabetes is expected in 2009, followed by filing for a fixed rimonabant/metformin combination in 2010.

Results from the STRADIVARIUS study, evaluating rimonabant in atherosclerosis, will be presented to the American College of Cardiology in March 2008, and the results of the ADAGIO trial, evaluating rimonabant in patients with dyslipidemia, will be presented to the European Atherosclerosis Society in April 2008..

Enrolment of patients to the CRESCENDO morbidity/mortality study is ongoing. Over 14,000 out of the planned 17,000 have been enrolled to date.

Thrombosis

After consultation with the healthcare authorities, the large-scale phase III program for the ultra low molecular weight heparin AVE5026, involving over 10,000 patients, is being put into place. Positive results from phase IIb point to AVE5026 as a potential successor to Lovenox. AVE5026 is a powerful anti-coagulant with pharmaco-dynamic properties that go beyond anti-Xa factor activity. It is not associated with food interaction due to the subcutaneous mode of administration, giving total bioavailability. AVE5026 has the potential to offer better tolerance (reduced bleeding, no drug interaction, antiXa/IIa ratio of over 30). Filing for approval is scheduled for 2010 in the prevention of venous thromboembolic events in patients requiring hip or knee replacement, receiving chemotherapy or undergoing abdominal surgery.

Filing for approval in the prevention of venous thromboembolic events in medical patients is scheduled for 2011.

Idrabiotaparinux (biotinylated idraparinux) is a long-acting selective neutralizable factor Xa coagulation inhibitor, administered by weekly subcutaneous injection. Enrolment of patients to the EQUINOX bioequipotency study in deep vein thrombosis is now complete, and one-third of the patient population for the CASSIOPEA study in pulmonary embolism has been recruited to date. Filing for approval in the treatment of deep vein thrombosis and pulmonary embolism is scheduled for 2009.

Enrolment to the BOREALIS-AF comparative study, designed to assess the efficacy of biotinylated idraparinux versus anti vitamin K in the prevention of stroke and systemic embolism in patients with atrial fibrillation, has now begun. Filing for approval in this indication is scheduled for 2011.

Given the results from AVE5026, and as part of the portfolio rationalization process, sanofi-aventis has decided to discontinue the development of hexadecasaccharide.

Cardiovascular

Results from the ATHENA study, assessing the potential morbidity/mortality benefits of Multaq(R) /Dronedarone, will be presented to the American Heart Rate Society at San Francisco in May 2008. A submission for approval by the healthcare authorities could be filed in mid-2008.

Phase IIb is ongoing for ilepatril, a novel anti-hypertensive for uncontrolled hypertension that inhibits ACE/NEP receptors. The final results will be presented to the American Heart Association at New Orleans in November 2008. The preliminary results are being used as the basis for ongoing discussions with the healthcare authorities on the phase III program.

The TAMARIS phase III program, a 1-year evaluation of the effectiveness of NV1FGF (a highly innovative gene therapy) in reducing the number of amputations in patients with critical lower limb ischemia, is under way. Filing for approval in this indication is scheduled for 2010.

Central Nervous System

Results from the EPLILONG phase III study demonstrate that eplivanserin, a 5-HT2A antagonist, significantly reduces WASO (Wake After Sleep Onset) and the number of nocturnal wakings reported by the patient at 6 to 12 weeks, compared with placebo.

This beneficial effect on sleep has also been confirmed by polysomnography in the results from the EPOCH phase III study, which showed that eplivanserin reduces WASO at 3 weeks (significant difference) and 6 weeks and nocturnal waking (significant difference at 3 to 6 weeks), versus placebo.

In both studies, eplivanserin demonstrated a good tolerance profile versus placebo with no residual effect on waking as measured by psychometric tests, and with no rebound phenomenon or withdrawal symptoms.

The GEMS phase III study, evaluating WASO at 12 weeks as reported by the patient, is ongoing. Filing for approval of Eplivanserin is scheduled for the second half of 2008.

The decision to file for approval of amibegron, a selective beta 3 receptor agonist for major depressive disorders, will be made on the basis of the results from three studies, SIRIUS -short-term efficacy-, CALYPSO -maintenance of efficacy-, ALBERIO -in combination with another anti-depressant-.

Results from two phase III studies evaluating the NK2 receptor antagonist saredutant in major depressive disorders are expected in the second quarter of 2008. The INDIGO study is assessing saredutant in elderly patients, while the MAGENTA study is evaluating maintenance of efficacy.

Filing for approval in the treatment of major depressive disorders is scheduled for the third quarter of 2008.

Results from studies involving saredutant in association with SSRI anti- depressants are expected in 2009. This program aims to address the acknowledged inadequacies in monotherapy anti-depressant regimens by showing the benefits of a strategy of treating major depressive disorders directly with saredutant in association with another anti-depressant.

A decision has been taken to discontinue the development of Dianicline.

Oncology

The database lock for the FLAGS phase III study, evaluating S-1 (alliance with Taiho) plus cisplatin as a first-line treatment for patients with advanced gastric cancer, is due to be completed in the first half of 2008. S-1 is a new oral anti-cancer agent derived from 5-FU which combines 3 pharmacological agents.
Two new phase III studies are in the initial phase:

-- A study evaluating S-1 versus 5-FU as a second-line treatment for

pancreatic cancer. Filing for approval in this indication is scheduled

in 2010.

-- A study evaluating S-1 as a first-line treatment in association with

Eloxatin(R) in 2,000 patients with metastatic colorectal cancer. Filing

for approval in this indication is scheduled in 2011.

The database lock for the phase III study evaluating aflibercept (VEGF Trap, alliance with Regeneron) as a third-line treatment for advanced ovarian cancer is due to be completed in the second quarter of 2008. Aflibercept has a novel mechanism of action and its properties, as compared with monoclonal antibodies, give it the potential to be a more powerful anti-angiogenesis agent with a broader spectrum of activity.
Enrolment has started in 4 pivotal phase III studies:

-- first-line treatment of hormone refractory prostate cancer (in

association with Taxotere(R)/prednisone);

-- second-line treatment of colorectal cancer (in association with the

FOLFIRI regimen);

-- second-line treatment of non small cell lung cancer (in association

with Taxotere(R));

-- first-line treatment of pancreatic cancer (in association with

gemcitabine).

The TRIST study, evaluating the therapeutic vaccine TroVax(R) (collaboration with Oxford Biomedica) as a first-line treatment for metastatic renal cancer in association with interleukin-2, interferon or sunitinib, has enrolled 577 patients out of a target population of 700. In the second quarter of 2008, enrolment will begin as planned for a study evaluating TroVax(R) as a first-line treatment in association with FOLFOX or FOLFIRI (+/- bevacizumab) in 1,300 metastatic colorectal cancer patients. Submission in metastatic renal cancer is scheduled for 2009, and in metastatic colorectal cancer for 2013.

The phase III study evaluating the second-generation taxoid larotaxel as a second-line treatment for pancreatic cancer is under way, with 104 patients out of 430 enrolled to date. Filing for approval is scheduled for 2009.

Vaccines

At the end of 2007, sanofi-aventis filed for approval in Europe of the first influenza vaccine to use a new delivery system (intradermic micro- injection). Filing in the United States is scheduled for 2009.

A number of other influenza vaccine R&D programs made significant progress during 2007:
-- The improved formulation intramuscular vaccine program, designed to

vaccinate the elderly against seasonal influenza. Filing for approval

in the United States is scheduled for the second quarter of 2008.

-- The phase II cell culture based vaccine program. A long-term alliance

agreement has been signed with Lonza for industrial-scale production.

-- In the field of preparedness for pandemic influenza, sanofi pasteur

received FDA approval in 2007 for the first H5N1 vaccine to be

registered in the United States, and has also filed for approval of a

vaccine of the same type in Europe. Encouraging results have also been

obtained for an optimized low-dose H5NI vaccine using a new adjuvant.

The Menactra(R) Toddler program to develop a meningococcal meningitis vaccine for very young children is ongoing, with 2009 the target date for filing. The most recent information request by the FDA on Pentacel, was provided at the end of 2007.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE: SNY).

Contacts: Jean-Marc Podvin, jean-marc.podvin@sanofi-aventis.com, Phone: 33 1 53 77 42 23

Forward-Looking Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward- looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward- Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi- aventis does not undertake any obligation to update or revise any forward- looking information or statements.

Recent Events

November 7, 2007 Presentation at the Scientific Sessions of

the American Heart Association (AHA) of a

retrospective analysis which found that

initiation of insulin glargine in patients

with type 2 diabetes was associated with a

lower incidence rate of myocardial

infarction as compared with NPH Insulin

November 7, 2007 Announcement of the start of phase II

testing of sanofi pasteur's cell culture-

based seasonal influenza vaccine

November 6, 2007 Presentation by sanofi pasteur to the

American Society of Tropical Medicine and

Hygiene (ASTMH) of positive results in the

development of a vaccine for the worldwide

prevention of dengue fever

November 10, 2007 Presentation at the Congress of the American

College of Allergy, Asthma & Immunology

(ACAAI) of new data giving further

information on the safety and efficacy of

Nasacort(R) AQ in children aged 2-5 years

old with year-round allergic rhinitis

November 13, 2007 Announcement of the signature of an

exclusive global collaboration agreement

between sanofi pasteur and Acambis plc for

the development and marketing of a West Nile

virus vaccine

November 13, 2007 Announcement that the European Commission

had endorsed the positive opinion of the

EMEA on Acomplia(R), to include the results

of the SERENADE study in the European label

November 19, 2007 Announcement of FDA approval for Avalide(R)

(irbesartan, hydrochlorothiazide) as the

first combination therapy for initial use in

patients likely to need multiple drugs to

achieve blood pressure goals

November 26, 2007 Announcement of the signature in Beijing of

an agreement between the Chinese authorities

and sanofi-aventis to build a facility to

manufacture influenza vaccine in China

November 29, 2007 Announcement of the signature of a global,

strategic collaboration agreement with

Regeneron to discover, develop, and

commercialize fully-human therapeutic

antibodies utilizing Regeneron's proprietary

VelociSuite of technologies

November 30, 2007 Announcement by sanofi-aventis and Astellas

of an agreement to restructure their joint

venture activities in Japan (Fujisawa

sanofi-aventis K.K.)

December 3, 2007 Inauguration by sanofi-aventis of its first

Asian development centre for

pharmaceuticals, in Goa (India)

December 10, 2007 Presentation to the American Society of

Hematology (ASH) of the results of the TREK

dose-ranging study on AVE5026 (a new

injectable anticoagulant), demonstrating a

highly statistically significant dose

response

December 13, 2007 Oral Presentation of the US Oncology

Adjuvant Trial 9735 at the 2007 San Antonio

Breast Cancer Symposium, showing that

Taxotere(R) and cyclophosphamide improved

overall survival versus an anthracycline

combination

January 3, 2008 Announcement of the signature of an

agreement between sanofi pasteur and Crucell

for a next-generation rabies vaccine

January 28, 2008 Announcement of approval for marketing in

Japan of Lovenox(R) for the prevention of

venous thrombo-embolism in patients

undergoing orthopedic surgery of the lower

limbs such as total hip replacement, total

knee replacement and hip fracture surgery

Financial Timetable

April 30, 2008 2008 first-quarter net sales and results

May 14, 2008 Shareholders' Annual General Meeting

July 31, 2008 2008 second-quarter net sales and results

October 31, 2008 2008 third-quarter net sales and results

Appendices

List of appendices

Appendix 1: Explanatory Notes/Financial Indicators

Appendix 2: 2007 fourth-quarter, full-year, first-quarter, second-quarter

and third-quarter net sales by product

Appendix 3: 2007 fourth-quarter and full-year adjusted consolidated

income statements

Appendix 4: 2007 fourth-quarter and full-year reconciliation of

consolidated income statement to adjusted consolidated income

statement

Appendix 5: Simplified consolidated statement of cash flows and

consolidated balance sheet

Appendix 6: Trends in selected items in the adjusted income statement

Appendix 1: Explanathe U.S. dollar. Changes in Group structure had a favorable effect of 0.4 of a point, reflecting the consolidation of net sales of Ticlid in Japan from October 1. On a reported basis, net sales fell by 6.0%.

2007 full-year net sales rose by 2.8% to euro 28,052 million. Exchange rate movements had an unfavorable effect of 3.8 points. Changes in Group structure had an unfavorable effect of 0.1 of a point over the year as a whole. After taking account of these effects, net sales fell by 1.1% on a reported basis.

The group net sales consist of sales of pharmaceuticals division (90.1%) and sales of vaccines division (9.9% versus 8.9% in 2006)

Net sales by division - Pharmaceuticals

Fourth-quarter net sales for the pharmaceuticals business were euro 6,262 million, down 0.6%. Net sales of the top 15 products were down 0.3% at euro 4,174 million, representing 66.7% of pharmaceuticals net sales against 66.5% for the comparable period of 2006.

Excluding the impact of the introduction of generics(4) of Ambien(R) IR in the United States and Eloxatin(R) in Europe, the top 15 products would have recorded growth of 9.5%.

Over 2007 as a whole, net sales for the pharmaceuticals business were up 1.7% at euro 25,274 million. Net sales of the top 15 products rose by 3.2% to euro 17,071 million, representing 67.5% of pharmaceuticals net sales against 66.5% in 2006. Excluding the impact of the introduction of generics(4) of Ambien(R) IR in the United States and Eloxatin(R) in Europe, the top 15 products would have recorded growth of 10.7% in 2007.

Change on a Change on a

Q4 2007 comparable FY 2007 comparable

euro million net sales basis net sales basis

Lovenox(R) 674 +17.4% 2,612 +13.4%

Plavix(R) 609 +14.0% 2,424 +9.5%

Lantus(R) ory Notes/Financial Indicators

Comparable net sales

When we refer to the change in our sales on a "comparable" basis, we mean that we exclude the impact of exchange rate movements and changes in Group structure (acquisitions and divestments of interests in entities and rights to products, and changes in consolidation method for consolidated entities).

We exclude the impact of exchange rates by recalculating sales for the prior period on the basis of exchange rates used in the current period. We exclude the impact of acquisitions by including sales from the acquired entity or product rights for a portion of the prior period equal to the portion of the current period during which we owned them, based on sales information we receive from the party from whom we make the acquisition.

Similarly, we exclude sales in the relevant portion of the prior period when we have sold an entity or rights to a product.

For a change in consolidation method, the prior period is recalculated on the basis of the method used for the current period.

Reconciliation of 2006 fourth-quarter/full-year net sales to 2006 fourth- quarter/full-year comparable net sales:

euro million Q4 2006

2006 fourth-quarter net sales 7,356

Impact of changes in Group structure 29

Impact of exchange rates (321)

2006 fourth-quarter comparable net sales 7,064

euro million FY 2006

2006 full-year net sales 28,373

Impact of changes in Group structure (15)

Impact of exchange rates (1,069)

2006 full-year comparable net sales 27,289

Worldwide presence of a product

When we refer to the "worldwide presence" of a product, we mean our consolidated net sales of that product, minus sales of the product to our alliance partners plus non-consolidated sales made through our alliances with Bristol-Myers Squibb on Plavix(R)/Iscover(R) (clopidogrel) and Aprovel(R)/Avapro(R)/Karvea(R) (irbesartan), based on information provided to us by our alliance partner.

Operating income - current

We define "operating income - current" as operating income before restructuring, impairment of property, plant and equipment and intangibles, gains/losses on disposals, and litigation.

Adjusted net income

We define "adjusted net income" as accounting net income after minority interests adjusted to exclude (i) the material impacts of the application of purchase accounting to acquisitions and (ii) acquisition-related integration and restructuring costs. We believe that eliminating these impacts from net income gives investors a better understanding of the underlying economic performance of the combined Group.

The material impacts of the application of purchase accounting to acquisitions, primarily the acquisition of Aventis, are as follows:

-- charges arising from the remeasurement of inventories at fair value,

net of tax;

-- amortization/impairment expense generated by the remeasurement of

intangible assets, net of tax;

-- any impairment of goodwill.

We also exclude from adjusted net income any integration and restructuring costs (net of tax) that are specific to the acquisition of Aventis by sanofi- aventis.

Q4 2007

Q4 2007 adjusted FY 2007

consolidated consolidated FY 2007 adjusted

financial financial consolidated consolidated

statements statements financial financial

euro million (unaudited) (unaudited) statements statements

Net sales 6,911 6,911 28,052 28,052

Net income (after

minority interests) 753 1,462 5,263 7,110

Basic EPS 0.56 1.09 3.91 5.28

Appendix 2: 2007 fourth-quarter and full-year net sales by product

2007 fourth-quarter net sales by product:

Q4 2006 Q4 2006

Q4 2007 comparable reported

euro million net sales net sales net sales

Lovenox(R) 674 574 614

Plavix(R) 609 534 541

Lantus(R) 552 420 451

Taxotere(R) 476 415 437

Eloxatin(R) 365 376 402

Stilnox(R)/Ambien(R)/Ambien CR(TM) 185 523 580

Copaxone(R) 280 253 273

Aprovel(R) 277 263 265

Tritace(R) 195 272 271

Allegra(R) 148 150 163

Amaryl(R) 101 101 105

Actonel(R) 81 85 87

Depakine(R) 80 73 74

Xatral(R) 84 81 84

Nasacort(R) 67 68 74

TOTAL 4,174 4,188 4,421

Other products 2,088 2,110 2,129

TOTAL Pharmaceuticals 6,262 6,298 6,550

Vaccines 649 766 806

TOTAL Net sales 6,911 7,064 7,356

2007 full-year net sales by product:

FY 2006 FY 2006

FY 2007 comparable reported

euro million net sales net sales net sales

Lovenox(R) 2,612 2,303 2,435

Plavix(R) 2,424 2,214 2,229

Lantus(R) 2,031 1,575 1,666

Taxotere(R) 1,874 1,675 1,752

Eloxatin(R) 1,521 1,606 1,693

Stilnox(R)/Ambien(R)/Ambien

CR(TM)/ Myslee(R) 1,250 1,868 2,026

Copaxone(R) 1,177 1,005 1,069

Aprovel(R) 1,080 1,007 1,015

Tritace(R) 741 963 977

Allegra(R) 706 637 688

Amaryl(R) 392 433 451

Actonel(R) 320 348 351

Depakine(R) 316 299 301

Xatral(R) 333 343 353

Nasacort(R) 294 263 283

TOTAL 17,071 16,539 552 +31.4% 2,031 +29.0%

Taxotere(R) 476 +14.7% 1,874 +11.9%

Eloxatin(R) 365 -2.9% 1,521 -5.3%

Stilnox(R)/Ambien(R)/

Ambien CR(TM)/Myslee(R) 185 -64.6% 1,250 -33.1%

Copaxone(R) 280 +10.7% 1,177 +17.1%

Aprovel(R) 277 +5.3% 1,080 +7.2%

Tritace(R) 195 -28.3% 741 -23.1%

Allegra(R) 148 -1.3% 706 +10.8%

Amaryl(R) 101 0.0% 392 -9.5%

Actonel(R) 81 -4.7% 320 -8.0%

Depakine(R) 80 +9.6% 316 +5.7%

Xatral(R) 84 +3.7% 333 -2.9%

Nasacort(R) 67 -1.5% 294 +11.8%

TOTAL TOP 15 4,174 -0.3% 17,071 +3.2%

TOTAL TOP 15 excluding

Eloxatin(R) in Europe and

Ambien(R) IR in the USA

(from April) 4,065 +9.5% 16,565 +10.7%

Fourth-quarter net sales of other pharmaceutical products were down 1.0% at euro 2,088 million. 2007 full-year net sales of other pharmaceutical products were down 1.5% at euro 8,203 million. In the "Other Countries" region, these products reported growth of 4.1% to euro 2,564 million; in Latin America, growth was even stronger at 10.2% (euro 918 million).

Geographical split of consolidated net sales by product (Top 15)

Change Change Change

on a on a on a

Q4 2007 net sales comparable United comparable Other comparable

(euro million) Europe basis States basis Countries basis

Lovenox(R) 201 +15.5% 395 +16.5% 78 +27.9%

Plavix(R) 422 +1.7% 37 +640.0% 150 +31.6%

Lantus(R) 168 +26.3% 321 +29.4% 63 +61.5%

Taxotere(R) 209 +16.8% 169 +8.3% 98 +22.5%

Eloxatin(R) 79 -36.3% 236 +12.4% 50 +19.0%

Stilnox(R)/Ambien(R)/

Ambien CR(TM)/

Myslee(R) 20 -16.7% 163 -65.8% 2 -91.3%

Copaxone(R) 84 +16.7% 188 +13.3% 8 -46.7%

Aprovel(R) 211 -0.5% - - 66 +29.4%

Tritace(R) 111 -9.8% 0 ns 84 -42.9%

Allegra(R) 8 -11.1% 74 -10.8% 66 +13.8%

Amaryl(R) 26 -23.5% 3 0.0% 72 +12.5%

Actonel(R) 51 -12.1% - - 30 +11.1%

Depakine(R) 55 +5.8% - - 25 +19.0%

Xatral(R) 41 -8.9% 28 +21.7% 15 +15.4%

Nasacort(R) 10 +11.1% 50 -3.8% 7 0.0%

Change Change Change

on a on a on a

FY 2007 comparable United comparable Other comparable

(euro million) Europe basis States basis Countries basis

Lovenox(R) 756 +9.4% 1,579 +14.8% 277 +16.9%

Plavix(R) 1,704 +5.3% 167 7.7% 553 +25.7%

Lantus(R) 627 +20.6% 1,200 +30.3% 204 +52.2%

Taxotere(R) 819 +14.5% 691 +6.5% 364 +17.0%

Eloxatin(R) 374 -33.7% 971 +9.8% 176 +11.4%

Stilnox(R)/Ambien(R)/

Ambien CR(TM)/

Myslee(R) 85 -11.5% 1,093 -35.0% 72 -20.0%

Copaxone(R) 324 +16.1% 801 +19.4% 52 -5.5%

Aprovel(R) 838 +3.8% - - 242 +21.0%

Tritace(R) 466 -8.8% 1 -92.9% 274 -37.4%

Allegra(R) 54 +3.8% 369 +4.8% 283 +21.5%

Amaryl(R) 116 -33.7% 9 -35.7% 267 +9.4%

Actonel(R) 204 -16.0% - - 116 +10.5%

Depakine(R) 216 +2.4% - - 100 +13.6%

Xatral(R) 167 -20.5% 107 +25.9% 59 +22.9%

Nasacort(R) 44 +10.0% 222 +13.3% 28 +3.7%

Comments by product

Net sales of Lovenox(R), the leading low molecular weight heparin on the market, rose by 17.4% in the quarter to euro 674 million. The product reported strong growth across all three regions: 16.5% in the United States, 15.5% in Europe, and 27.9% in the "Other Countries" region. In the United States, increased use in medical prophylaxis remains the main growth driver.

In January 2008, Lovenox(R) was approved in Japan for the prevention of venous thromboembolism (VTE) in patients undergoing orthopedic surgery of the lower limbs such as total hip replacement, total knee replacement and hip fracture surgery. Further clinical trials are ongoing to extend the product's indication in Japan to patients undergoing abdominal surgery who are at risk of venous thromboembolism.

Lantus(R) is the first insulin brand in the world to exceed euro 2 billion of sales (euro 2,031 million). In the fourth quarter, the product enjoyed strong growth across all three regions. The new SoloSTAR(R) disposable pen used to administer Lantus(R) is now available in most European countries and in the United States.

Findings presented at the American Heart Association's 2007 Scientific Sessions from a retrospective analysis of healthcare claims in more than 20,000 patients with type 2 diabetes found that the initiation of insulin therapy with insulin glargine (Lantus(R)) was associated with a lower incidence rate of subsequent myocardial infarction (MI), as compared with NPH insulin.

Taxotere(R) recorded further strong growth during the quarter in Europe (up 16.8%) and in the "Other Countries" region (up 22.5%). In the United States, net sales of the product were up 8.3%, in line with the growth rate achieved in the previous quarter.

In December, sanofi-aventis filed an application with the European Medicines Evaluation Agency (EMEA) to include Taxotere(R) in combination with Herceptin(R) as an adjuvant treatment for breast cancer, on the basis of the BCIRG-006 study.

In December, results presented to the 30th annual San Antonio Breast Cancer Symposium (SABCS) showed that for women with early stage breast cancer who have had surgery, experimental treatment with a combination of Taxotere(R) and cyclophosphamide significantly improved overall survival compared to standard anthracyclin-based chemotherapy. These results were based on a median follow-up of 7 years.

Ambien CR(TM) posted net sales of $190 million in the United States during the quarter and $751 million over the full year. Net sales of Ambien(R) IR, which went off patent in the United States on April 20, 2007, totaled euro 30 million in the fourth quarter, against euro 352 million in the comparable period of 2006. Full-year net sales of Ambien(R) IR were euro 538 million.

In Japan, sales of Myslee(R) (not consolidated by sanofi-aventis) rose by 6.4% in the fourth quarter to euro 34 million. Over 2007 as a whole, the product achieved growth of 9.8% to euro 118 million.

Under the terms of the agreement between sanofi-aventis and Astellas, sanofi-aventis will consolidate net sales generated by Myslee(R) in Japan with effect from January 1, 2008.

In the United States, Eloxatin(R), the market-leading colorectal cancer treatment as adjuvant and in the metastatic phase, recorded fourth-quarter net sales growth of 12.4% to euro 236 million. In Europe, where the introduction of generics is ongoing, fourth-quarter sales were down 36.3% at euro 79 million. In the "Other Countries" region, net sales of Eloxatin(R) rose by 19.0% to euro 50 million.

Net sales of Tritace(R), adversely impacted by generic competition in Canada, fell by 28.3% in the fourth quarter to euro 195 million.

Acomplia(R) posted net sales of euro 21 million in the fourth quarter and euro 79 million over the full year.

In November, the European Commission endorsed the positive opinion of the European Medicines Evaluation Agency (EMEA) for Acomplia(R), to include type 2 diabetes trial results into the European label (section 5.1). This decision was based on the results of the SERENADE study, the first clinical trial to assess Acomplia(R) in glycemic control for type 2 diabetic patients not already taking medication for their condition.

Xyzal(R), a new prescription oral antihistamine, was launched by sanofi- aventis and UCB in the United States at the start of October 2007. Fourth- quarter net sales were euro 8 million. At end December, Xyzal(R) accounted for 5.2% of new prescriptions (NRX IMS NPA weekly).

Worldwide presence(1) of Plavix(R) / Iscover(R)

Change Change

on a on a

comparable comparable

euro million Q4 2007 basis FY 2007 basis

Europe 458 +5.0% 1,808 +5.3%

United States 829 +239.8% 2,988 +50.4%

Other Countries 225 +27.8% 826 +22.9%

TOTAL 1,512 +76.6% 5,622 +28.5%

On June 19, 2007, the U.S. District Court for the Southern District of New York upheld the validity and enforceability of the U.S. patent covering clopidogrel bisulfate, the active ingredient of Plavix(R), and issued a permanent injunction enjoining Apotex from marketing its generic clopidogrel bisulfate in the United States prior to the expiration of the patent. Apotex had launched a generic clopidogrel bisulfate in August 2006, following which the U.S. District Court for the Southern District of New York awarded sanofi- aventis a temporary injunction on August 31, 2006 ordering Apotex to halt further sales of its generic clopidogrel bisulfate, without however ordering a recall of products already shipped. The main patent protection for this product has now been maintained in the United States until November 2011.

In the United States, sales of Plavix(R) (consolidated by BMS) reached $1,180 million in the fourth quarter, compared with $348 million in the fourth quarter of 2006 when the product was affected by the availability of a generic version. Full-year sales of Plavix(R) totaled $4,072 million, compared with $2,672 in 2006.

In Europe, fourth-quarter net sales of Plavix(R) were 5.0% higher at euro 458 million, though sales are still affected by parallel imports in Germany.

In the "Other Countries" region, sales growth is accelerating, reaching 27.8% in the fourth quarter (to euro 225 million), driven by the product's success in Japan where the pace of sales growth was boosted in May by the decision of the authorities to lift the two-week limit on prescriptions. Fourth quarter sales in Japan were euro 27 million, against euro 4 million in the comparable period of 2006. Over the full year, Plavix(R) recorded Japanese sales of euro 61 million, compared with euro 11 million in 2006.

(1) See Appendix 1 for a definition of financial indicators, and Appendix 6 for a description of selecte
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
2. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
3. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... A book about the self-discovery of one’s limitless creative power, “ Unleash Your ... give readers the courage they need to embrace their creativity and unleash it as ... my life to learn and create what I set my heart with no limits ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... "ProDrop 3D ... projects to the next level," said Christina Austin - CEO of Pixel Film Studios. ... Studios. With ProDrop 3D Abstract have the ability to generate and manipulate three-dimensional shapes ...
(Date:5/31/2016)... ... ... According to recent statistics, there are nearly half a million physical therapists ... physical therapy professional and every clinic has a duty to perform at the highest ... competitive industry is also essential. The solution that many physical therapy leaders turn to ...
(Date:5/31/2016)... (PRWEB) , ... June 01, 2016 , ... ... “ Psoriasis and smoking: links and risks ”. , As corresponding author Professor ... on the relation between smoking habits and psoriasis. Smoking influences the onset and ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... that considers individuals’ genetic characteristics and the physical and behavioral worlds in ... in sync. In personalized medicine, diagnosing an individual’s disease depends on accurately ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... May 31, 2016 Aloe vera ... food, cosmetics and pharmaceuticals, with global volume to surpass ... 1.6 Bn. Demand for aloe vera extracts ... yogurts will continue its upward momentum in 2016 as ... boost positive sentiment on aloe vera, with wide-ranging applications ...
(Date:5/31/2016)... , May 31, 2016 The global ... coupled with surging prevalence of deaths from chronic diseases. According ... By Region, By Country): Opportunities and Forecasts (2016-2021) - (By ... Orthopaedic, Cardiovascular, Plastic Surgery, Wound Care); By Region-North America, ... UK, Germany , Italy ...
(Date:5/31/2016)... May 31, 2016 , Isansys  Lifecare, ... its Patient Status Engine wireless patient monitoring platform, as it ... Germany , Scotland and ... 2 nd generation system, launched earlier this year, is now ... , , This new technology significantly enhances ...
Breaking Medicine Technology: